Related Experiment Videos
Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study
I Abdulkader1, L Sánchez, J Cameselle-Teijeiro
1Department of Pathology, School of Medicine, Clinical University Hospital, 15706 Santiago de Compostela, Spain. ihab.abdulkader.nallib@sergas.es
Oncology Reports
|November 8, 2005
Summary
This study investigated cell-cycle and apoptosis regulators in common epithelial cancers. Bcl-2 expression was linked to better survival, suggesting it as a key prognostic biomarker across cancer types.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Epithelial cancer progression involves dysregulated cell proliferation and apoptosis.
- Identifying common prognostic biomarkers is crucial for effective cancer management.
Purpose of the Study:
- To evaluate cell-cycle and apoptosis regulator expression in common carcinomas.
- To correlate these regulators with clinical outcomes for prognostic biomarker discovery.
- To establish cancer origin-independent biomarkers.
Main Methods:
- Tissue microarrays (TMAs) analyzed immuno-expression of Ki-67, Bcl-2, Bax, cyclins, CDKs, p16, p21, and p27.
- Study included 205 carcinomas: large bowel, breast, lung, and prostate.
- Univariate analysis correlated protein expression with patient survival.
Main Results:
- Positivity for p27, p16, and Bcl-2 correlated with improved overall survival.
- Lack of Bcl-2 expression increased mortality risk by 2.3-fold.
- Overlapping alterations in cell-cycle, apoptosis, and tumor suppressor pathways were observed.
Conclusions:
- Bcl-2 emerges as a significant biological factor influencing clinical behavior in common epithelial cancers.
- p27 and p16 also show prognostic value.
- Findings suggest potential for universal prognostic biomarkers in epithelial cancers.